Clinical Trials Logo
  1. Home
  2. Endophthalmitis
  3. NCT02595359
  4. Details
NCT02595359 Clinical Trial

Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Endophthalmitis Clinical Trial

Official title:
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02595359
Other study ID # 0001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2013
Est. completion date June 20, 2018

Study information
Verified date April 2019
Source Universidade Federal de Pernambuco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

Description:

Although cataract surgery is generally considered a safe procedure resulting in a favourable visual outcome, surgical complications do occur. The most feared complication is postoperative endophthalmitis which is an infectious condition caused by micro-organisms introduced to the interior of the eye during or after the surgical procedure.

As endophthalmitis is an infection, it should be preventable by antibiotic treatment.

Prophylactic antibiotic treatment can be given as topical treatment preoperatively, or during surgery directly into the anterior chamber, or as a subconjunctival, or it can be given as topical treatment postoperatively.

The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

Recruitment information / eligibility
Status Completed
Enrollment 1000
Est. completion date June 20, 2018
Est. primary completion date June 20, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 90 Years
Eligibility Inclusion Criteria:

- Diagnosis of visually significant cataract

Exclusion Criteria:

- Has known allergies to moxifloxacin

- Has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason

- Has a known history of a condition which causes an immuno-compromised host state

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Moxifloxacin
Moxifloxacin intracameral

Locations
Country Name City State
Brazil UFPE Ophthalmology Recife PE

Sponsors (1)
Lead Sponsor Collaborator
Universidade Federal de Pernambuco

Country where clinical trial is conducted

Brazil, 

Outcome
Type Measure Description Time frame Safety issue
Primary endothelial cell count 6-month; 1 year; 2 years
Secondary endophthalmitis incidence 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT04214821 - The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% Phase 1/Phase 2
Completed NCT00461656 - Povidone-iodine Antisepsis for Strabismus Surgery Phase 4
Completed NCT00136344 - Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery N/A
Completed NCT04568213 - Hypochlorous Acid Disinfection Prior to Cataract Surgery Phase 3
Terminated NCT01496794 - Endophthalmitis Cultures N/A
Completed NCT00406913 - Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery N/A
Recruiting NCT05079854 - Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis Phase 4
Recruiting NCT05432336 - Complex Ocular Infection, Optimization of Microbiological Diagnosis
Recruiting NCT02810587 - Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics N/A
Completed NCT00398658 - Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis Phase 4
Recruiting NCT04035369 - Endophthalmitis Post Intravitreal Injections N/A
Not yet recruiting NCT03420820 - Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection N/A
Recruiting NCT06268561 - Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months
Withdrawn NCT00335231 - Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery N/A
Not yet recruiting NCT03244072 - Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery Phase 2/Phase 3
Completed NCT01323868 - Endogenous Endophthalmitis in the Inpatient Setting N/A
Completed NCT03363295 - Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis Phase 4
Suspended NCT02590523 - Intracameral Antibiotic Safety Study Phase 3
Terminated NCT02770729 - Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis. Phase 3
Not yet recruiting NCT02324166 - Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain Phase 4